| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5402b86c97a41e7a06723b55dccc03a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0972d21603a9709cd5acfe2c4c026d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7282554a3e8b98a4d07a1586a2aee702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f9b991771f088fa52a2ceacd50b5f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8da929e9529b2614be3a8fba18095c30 |
| publicationDate |
2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021171621-A1 |
| titleOfInvention |
Monoclonal antibody binding to human il-5, preparation method therefor and use thereof |
| abstract |
Disclosed is a monoclonal antibody that binds to human IL-5. The monoclonal antibody that binds to human IL-5 has a good biological activity for inhibiting TF-1 cell proliferation induced by IL-5 and blocking the interaction between IL-5 and IL-5RA, has a different antigen epitope from the known anti-human IL-5 antibody, can be used for preparing drugs for treating diseases mediated by the over-expression of eosinophilic granulocytes (such as asthma), and has a good clinical application prospect. |
| priorityDate |
2017-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |